Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

New approaches in the management of multiple sclerosis.
Patient reported outcome measures in neurogenic bladder.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
Novel therapies for memory cells in autoimmune diseases.
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
US court permits generic version of Teva MS drug a year sooner
Pharmacology and therapeutic potential of interferons.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Federation of Clinical Immunology Societies 2012
Pregnancy outcomes in patients exposed to interferon beta-1b.
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
Fourth PML Case With Tecfidera in MS Calls for Vigilance
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.

Pages